Tiếng ViệtMaypharm’s botulinum toxin brands, Metox and Kamomis, are used in aesthetics and therapeutics. Metox is available in 100 and 200 units, while Kamomis offers 100 units, providing flexible options for practitioners. Despite COVID-19 and intense competition, Maypharm’s botulinum toxin revenue grew by 48% in 2022, reaching $8.1M, and increased by 33% in 2023. Growth was driven by strong sales in the Middle East, particularly from the launch of Metox 200 units. With proven product quality and sales success, Maypharm is expanding into the Asian market, establishing local branches and joint ventures in Indonesia and Vietnam to enhance market presence and diversify sales channels.
